SYRE — Spyre Therapeutics Share News
0.000.00%
Last trade - 00:00Spyre's inflammatory bowel drug reduces disease activity in mid-stage study
NASDAQ TRADE HALT HALT NEWS PENDING AT 06:55 AM
Brief: Spyre Announces Acceleration Of Expected Topline Readout Of Skyway Rheumatoid Arthritis Sub-Study To Q3 2026
Brief: Spyre Therapeutics Files For Mixed Shelf Of Up To $500 Million
Focus: Drugmakers turn to AI to speed trials, regulatory submissions
Brief: Spyre Therapeutics Inc - Skyline Trial In UC Completes SPY001 Enrollment Ahead Of Schedule
U.S. RESEARCH ROUNDUP- Autozone, Coursera, Lennar
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
U.S. STOCKS ON THE MOVE-Spyre Therapeutics, Astria, Walmart
Spyre Therapeutics rises after $275 mln equity raise
Brief: Spyre Therapeutics Inc - Expects $486.2 Million In Cash And Equivalents As Of Sept 30, 2025 - SEC Filing
Brief: Spyre Therapeutics Announces Pricing Of $275 Million Public Offering Of Common Stock
Spyre Therapeutics falls after stock offering launch
Brief: Spyre Doses First Patient In Phase 2 SKYWAY Trial of SPY072, First Anti-TL1A Antibody for Rheumatic Diseases
U.S. RESEARCH ROUNDUP- American Airlines, Jabil, Lennar
Spyre Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
U.S. STOCKS ON THE MOVE-Walgreens, Harley-Davidson, Hewlett Packard Enterprise
U.S. STOCKS ON THE MOVE-Spire Global, Broadcom, AGCO
U.S. STOCKS ON THE MOVE-Crypto stocks , WD-40, Old Dominion